Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)
MW McCarthy - Expert Opinion on Pharmacotherapy, 2022 - Taylor & Francis
ABSTRACT Introduction SARS-CoV-2, the virus that causes COVID-19, elicits a variety of
host responses ranging from asymptomatic or mild illness in most people, to severe disease …
host responses ranging from asymptomatic or mild illness in most people, to severe disease …
Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19).
MW McCarthy - Expert Opinion on Pharmacotherapy, 2022 - europepmc.org
ABSTRACT Introduction: SARS-CoV-2, the virus that causes COVID-19, elicits a variety of
host responses ranging from asymptomatic or mild illness in most people, to severe disease …
host responses ranging from asymptomatic or mild illness in most people, to severe disease …
[HTML][HTML] Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)
MW McCarthy - Expert Opinion on Pharmacotherapy, 2022 - ncbi.nlm.nih.gov
ABSTRACT Introduction: SARS-CoV-2, the virus that causes COVID-19, elicits a variety of
host responses ranging from asymptomatic or mild illness in most people, to severe disease …
host responses ranging from asymptomatic or mild illness in most people, to severe disease …
Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)
MW McCarthy - Expert opinion on pharmacotherapy, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction SARS-CoV-2, the virus that causes COVID-19, elicits a variety of host responses
ranging from asymptomatic or mild illness in most people, to severe disease and critical …
ranging from asymptomatic or mild illness in most people, to severe disease and critical …